JOIN US »
4th Advances in Circulating Tumor Cells (ACTC) Conference in Greece
Oct 2 – 5, 2019 | Corfu, Greece | Booth 12
Learn How New CTC Assays Can Play an Important Role in Lung and Bladder Cancer Management
Learn More About The Next Generation of Single-Cell Technology. Please join us as we partner with IncellDx at ACTC 2019 meeting in Corfu, Greece, on October 2–5, 2019 (www.actc2019.org). This year’s conference focuses on late-breaking news in CTCs, ctDNA, circulating miRNAs and extracellular vesicles technologies and their clinical applications. Our team will be there to schedule one-to-one office hours on the 3rd and 4th of October.
The Genesis System for CTC Enumeration. The lack of reproducibility and sensitivity with legacy technologies has limited the clinical adoption of circulating tumor cells (CTCs) for cancer monitoring. The Genesis System was developed by Celsee to address the shortcomings of single-cell analysis including CTC isolation and enumeration. Learn more »
Our Partnership With IncellDx. Celsee and IncellDx have partnered to provide a comprehensive suite of products to rapidly and conveniently evaluate your cancer patients from Primary Tumor to Monitoring Circulating Tumor Cells (CTCs). See how these new tools for screening primary lung and bladder tumors can monitor with ultra-sensitive CTC assays.
Dates, Booth & Presentation Information
Conference Dates: October 2nd – 5th, 2019
Main Oral Presentation Information
We invite you to attend our oral presentation on, “Combined Single-Cell Analysis of Solid Tumors and CTCs for Comprehensive Patient Management,” presented by Bruce Patterson, MD – CEO and Founder of IncellDx.
Non-small cell lung cancer (NSCLC) has a poor prognosis as most patients are at an advanced stage when diagnosed. However, targeted therapy and immunotherapy in recent years have significantly improved NSCLC patient outcome. See how we used single-cell immunophenotype and cancer biomarker profiling of primary tumor cells to investigate signatures that may predict the presence of circulating tumor cells (CTCs).
What you will learn. Learn more about our new comprehensive suite of products to help optimize yield and analysis of CTCs, as well as:
Profiling multiple immune and cancer markers on cancer samples with multi-parametric flow cytometry allow protein expression information at the single-cell level.
Clustering analysis of the proteomic data revealed a signature driven by checkpoint marker expression on CD103+CD4+ T cells that could potentially be predictive of CTCs.
Learn how new CTC assays can play an important role in lung and bladder cancer management
Date: Wednesday, October 2 | Time: 15:20 – 15:30 | Location: Kerkyra Ballroom
Poster Presentation Information
We invite you to attend our poster presentation on, “Single Cell Immuno- and Cancer Marker Profiling of Non-small Cell Lung Cancer Tissue: Checkpoint Marker Expression on CD103+, CD4+ T-Cells Correlates with Circulating Tumor Enumeration,” presented by Bruce Patterson, MD – CEO and Founder of IncellDx.
Date: Wednesday, October 2 | Time: 7:30 – 8:15 | Location: Nausica Ballroom